Intracavernous growth differentiation factor-5 therapy enhances the recovery of erectile function in a rat model of cavernous nerve injury

J Sex Med. 2008 Aug;5(8):1866-75. doi: 10.1111/j.1743-6109.2008.00881.x. Epub 2008 Jun 28.

Abstract

Introduction: Neurogenic erectile dysfunction remains a serious complication in the postprostatectomy population. Effective protective and regenerative neuromodulatory strategies are needed.

Aim: To determine the effect of growth differentiation factor-5 (GDF-5) on erectile function and its mechanism in a rat model of cavernous nerve (CN) injury.

Main outcome measures: Erectile function was assessed by CN electrostimulation at 4 weeks. Penile tissues were examined by real-time polymerase chain reaction (PCR) and immunohistochemical analyses.

Methods: Forty-eight male Sprague-Dawley rats were randomly divided into six equal groups: one group underwent sham operation (uninjured controls), while five groups underwent bilateral CN crush. Crush-injury groups were treated at the time of injury with intracavernous injection of a slow-release suspension of liquid microparticles containing no GDF-5 (vehicle), 0.4 microg (low concentration), 2 microg (intermediate concentration), or 10 microg GDF-5 (high concentration). One untreated group served as injured controls.

Results: GDF-5 enhanced erectile recovery and significantly increased intracavernous pressure in the low and intermediate-concentration groups vs. injured controls. Low-concentration GDF-5 demonstrated the best functional preservation, as the intracavernous pressure increase in this group did not differ significantly from uninjured controls. A dose-response relationship was confirmed for the effects of GDF-5 in penile tissue. Low-concentration GDF-5 showed better preservation of the penile dorsal nerves and antiapoptotic effects in the corpus cavernosum (P < 0.05 vs. injured controls). Although high concentration GDF-5 did not confer meaningful erectile recovery, this dose was more effective at decreasing transforming growth factor-beta than low-concentration GDF-5.

Conclusions: Intracavernous injection of low (0.4 microg) or intermediate-concentration GDF-5 (2 microg) was effective in preserving erectile function in a rat model of neurogenic erectile dysfunction. The underlying mechanism appears to involve neuron preservation and antiapoptosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Blood Pressure / drug effects
  • Disease Models, Animal*
  • Dose-Response Relationship, Drug
  • Erectile Dysfunction / drug therapy*
  • Erectile Dysfunction / pathology
  • Gene Expression / drug effects
  • Growth Differentiation Factor 5 / administration & dosage*
  • In Situ Nick-End Labeling
  • Injections
  • Male
  • Nerve Crush
  • Nitric Oxide Synthase / metabolism
  • Penile Erection / drug effects
  • Penis / blood supply
  • Penis / drug effects
  • Penis / innervation*
  • Penis / pathology
  • Peripheral Nerve Injuries*
  • RNA, Messenger / genetics
  • Rats
  • Rats, Sprague-Dawley
  • Transforming Growth Factor beta / genetics

Substances

  • Growth Differentiation Factor 5
  • RNA, Messenger
  • Transforming Growth Factor beta
  • Nitric Oxide Synthase